Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition

Overview

This is an open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, oral bioequivalence study.

Full Title of Study: “Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10 mg in Healthy, Adult, Human Subjects Under Fasting Condition.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2009

Detailed Description

The study was an open label, balanced, randomized, two-treatment, two-period, two sequence,single dose, crossover, oral bioequivalence study of Donepezil Hydrochloride tablets 10 mg of Dr. Reddy's Laboratories Limited, India comparing with that of ARICEPT® (containing Donepezil Hydrochloride) tablets 10 mg of Pfizer Inc, New York, 10017 in healthy, adult, human subjects under fasting condition. 28 subjects are enrolled in the study, and 26 subjects are completed the study.

Interventions

  • Drug: Donepezil Hydrochloride
    • Donepezil Hydrochloride Tablets 10 mg
  • Drug: Aricept
    • Aricept 10 mg Tablets

Arms, Groups and Cohorts

  • Experimental: Donepezil Hydrochloride10 mg Tablets
    • Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy’s Laboratories Limited
  • Active Comparator: Aricept 10 mg Tablets
    • Aricept 10 mgTablets of Pfizer Inc

Clinical Trial Outcome Measures

Primary Measures

  • Area unde curve (AUC)
    • Time Frame: Pre-dose 0.5,0.75,1,1.5,2,2.5,3,3.5,4,4.5,5,5.5,6,7,8,9,10,12,16,24,36,48,72,96,120,144,168,192,216,240 and 264 hours post-dose

Participating in This Clinical Trial

Inclusion Criteria

  • Provide written informed consent. – Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg. – Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight in Kg/height in m2. – Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician / investigator to be of no clinical significance). – Female Subjects – Of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence. – Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject) Exclusion Criteria:

  • Incapable of understanding the informed consent. – Systolic blood pressure less than 90 mm of Hg 140 mm of Hg. – Diastolic blood pressure less than 60 mm of Hg 90 mm of Hg. – Oral temperature is below 95.0°F or above 98.6°F. – Pulse rate below 50/min or above 100/min. – History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs. – Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function. – Consumption of grapefruit for the past ten days prior to the check-in, in each period. – Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period. – Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period. – Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period. – Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing. – Clinically significant abnormalities and / or with significant diseases. – Confirmed positive in alcohol screening. – Confirmed positive in selected drug of abuse. – Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study. – Confirmed positive in urine pregnancy test. – Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Dr. Reddy’s Laboratories Limited
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Dr. L Krishna Murthy, Principal Investigator, Bioserve Clinical Research Private Limited

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.